Identification of FOS as a Candidate Risk Gene for Liver Cancer by Integrated Bioinformatic Analysis

Table 5

Univariate and multivariate analyses of factors associated with TTR.

Clinical and pathologic indexes		Univariate		Multivariate
		HR (95% CI)		HR (95% CI)
Gender	(Male vs. female)	0.99 (0.82, 1.20)	0.91	N/A	N/A
Age, y	(≤50 vs. >50)	0.87 (0.77, 1.00)	0.04	0.90 (0.78, 1.04)	0.15
HBsAg	(Positive vs. negative)	1.74 (1.52, 2.00)	0.00	1.64 (1.41, 1.91)	0.00
Liver cirrhosis	(No vs. yes)	0.75 (0.42, 1.33)	0.32	N/A	N/A
Portal lymph node	(Negative vs. positive)	0.66 (0.35, 1.24)	0.19	N/A	N/A
AFP (ng/ml)	(≤400 vs. >400)	1.30 (1.15, 1.48)	0.00	1.11 (0.96, 1.27)	0.16
MVI	(None vs. yes)	1.05 (0.91, 1.22)	0.50	N/A	N/A
Tumor number	(Multiple vs. single)	1.18 (1.03, 1.36)	0.02	1.35 (1.16, 1.57)	0.00
Tumor size, cm	(≤5 vs. >5)	1.52 (1.33, 1.74)	0.00	1.43 (1.23, 1.66)	0.00
PVTT	(None vs. yes)	0.75 (0.66, 0.86)	0.00	0.93 (0.80, 1.07)	0.30
GGT (U/L)	(≤54 vs. >54)	1.21 (1.05, 1.39)	0.01	1.01 (0.87, 1.19)	0.86
Tumor encapsulation	(None vs. complete)	0.80 (0.71, 0.91)	0.00	0.94 (0.82, 1.08)	0.37
Edmondson stage	(II-IV vs. I-II)	0.81 (0.71, 0.92)	0.00	0.81 (0.70, 0.93)	0.00
FOS	(Negative vs. positive)	0.79 (0.69, 0.90)	0.00	0.79 (0.68, 0.90)	0.00

AFP, α-fetoprotein; MVI, microvascular invasion; PVTT, portal vein tumor thrombus; GGT, γ-glutamyl transpeptidase; FOS, Fos protooncogene; HR, hazard ratio. Univariate analysis and multivariate analysis and cox proportional hazards regression model. and .